Intra-Cellular Therapies
ITCI
$67.24
Share price
2.42%
Change (1 day)
12.95%
Change (1 year)
Categories
Intra-Cellular Therapies (ITCI) - P/B ratio
P/B ratio as of June 2024 : 11.7
According to Intra-Cellular Therapies's latest financial reports the company has a price-to-book ratio of 11.7.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Intra-Cellular Therapies - P/B ratio (from 2013 to 2024)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2024-12-31 | N/A | -100% |
| 2023-12-31 | 11.7 | 52.56% |
| 2022-12-31 | 7.64 | -25.13% |
| 2021-12-31 | 10.2 | 161.93% |
| 2020-12-31 | 3.90 | -60.11% |
| 2019-12-31 | 9.77 | 396.25% |
| 2018-12-31 | 1.97 | 13.16% |
| 2017-12-31 | 1.74 | 0.01% |
| 2016-12-31 | 1.74 | -64.33% |
| 2015-12-31 | 4.87 | 12.86% |
| 2014-12-31 | 4.32 | -69.19% |
| 2013-12-31 | 14.0 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Xencor XNCR | 2.41 | -79.46% | 🇺🇸 USA |
 MediciNova MNOV | 1.10 | -90.63% | 🇺🇸 USA |
 Curis CRIS | 6.62 | -43.49% | 🇺🇸 USA |